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Vicriviroc (formerly SCH 417690), a CCR5 receptor
antagonist, is currently under investigation for the treat-
ment of HIV infection. Human liver microsomes (HLM)
metabolized vicriviroc via N-oxidation (M2/M3), O-
demethylation (M15), N, N-dealkylation (M16), N-
dealkylation (M41) and carboxylic acid formation
(M35b/M37a). The metabolites generated under in vitro
conditions were also detected in clinical studies after oral
doses of vicriviroc. Incubation with recombinant human
CYP3A4 formed all metabolites listed above, while
CYP2C9 formed M15 and CYP3A5 formed M2/M3 and
M41.
In clinical trials, vicriviroc co-administered with ≥100 mg
QD ritonavir (RTV), a potent CYP 3A4 inhibitor, resulted
in a Cmax 2 to 3 times higher and an AUC(0–12 hr) 4 to
5 times higher than vicriviroc alone. In vitro pre- or co-
incubation inhibition studies with HLM demonstrated
that vicriviroc does not significantly inhibit the activities
of CYPs 1A2, 2A6, 2D6, 2C9, 3A4, or 2C19 at concentra-
tions up to 26.7 µg/mL (100 X the expected human
plasma Cmax following once daily oral doses of 10 mg +
RTV), which suggests that vicriviroc is not an inhibitor of
major CYP enzymes.
The results suggest that formation of the major vicriviroc
metabolites in human liver microsomes is primarily
mediated via CYP3A4, and that vicriviroc, at clinically rel-
evant doses, is unlikely to inhibit other co-administered
drugs metabolized by the major CYP 450 enzymes.
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